Quốc gia: Canada
Ngôn ngữ: Tiếng Anh
Nguồn: Health Canada
PROTEASE; LIPASE; AMYLASE
NESTLE ENTERPRISES S.A.
A09AA02
MULTIENZYMES (LIPASE, PROTEASE ETC)
57100UNIT; 10440UNIT; 56400UNIT
TABLET
PROTEASE 57100UNIT; LIPASE 10440UNIT; AMYLASE 56400UNIT
ORAL
100
Prescription
DIGESTANTS
Active ingredient group (AIG) number: 0302964042; AHFS:
APPROVED
2020-07-02
IMPORTANT: PLEASE READ _ _ _VIOKACE_ _TM_ _ – Pancrelipase Tablets _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _Page 1 of 17_ PRODUCT MONOGRAPH PR VIOKACE TM Pancrelipase tablets 10,440 USP and 20,880 USP units of lipase USP Pancreatic enzymes A09AA02 Nestlé Enterprises S.A. 12, rue Entre-deux-Villes 1800 Vevey, Switzerland Distributed by: Accelera Pharma Canada Inc. Mississauga, ON, L5L 5Z9 Date of Initial Approval: March 25, 2015 Date of Revision: July 3, 2020 Submission Control No: 239610 IMPORTANT: PLEASE READ _ _ _VIOKACE_ _TM_ _ – Pancrelipase Tablets _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _Page 2 of 17_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ........................................................................ 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 5 DRUG INTERACTIONS ................................................................................................... 6 DOSAGE AND ADMINISTRATION ............................................................................... 7 OVERDOSAGE .................................................................................................................. 8 ACTION AND CLINICAL PHARMACOLOGY .............................................................. 8 STORAGE AND STABILITY ........................................................................................... 8 SPECIAL HANDLING INSTRUCTIONS ......................................................................... 9 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................. Đọc toàn bộ tài liệu